These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36305094)

  • 1. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
    Lin X; Lin X; Guo L; Wang Y; Zhang G
    Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
    Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
    Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
    Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
    Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
    Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant
    Lin XY; Guo L; Lin X; Wang Y; Zhang G
    J Breast Cancer; 2023 Aug; 26(4):363-377. PubMed ID: 37565929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
    Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
    Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
    Li K; Liao N; Chen B; Zhang G; Wang Y; Guo L; Wei G; Jia M; Wen L; Ren C; Cao L; Mok H; Li C; Lin J; Chen X; Zhang Z; Hou T; Li M; Liu J; Balch CM; Liao N
    Breast Cancer Res Treat; 2020 Sep; 183(2):321-332. PubMed ID: 32638235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
    Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
    Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of
    Cao L; Ren C; Zhang G; Li X; Chen B; Li K; Li C; Mok H; Wang Y; Wen L; Jia M; Wei G; Lin J; Liao N
    DNA Cell Biol; 2022 May; 41(5):521-538. PubMed ID: 35475703
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.
    Zhang L; Sun S; Zhao X; Liu J; Xu Y; Xu L; Song C; Li N; Yu J; Zhao S; Yu P; Fang F; Xie J; Ji X; Yu R; Ou Q; Zhao Z; Li M
    Mol Oncol; 2022 Oct; 16(20):3689-3702. PubMed ID: 35971249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
    Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y
    Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations and prognosis of breast cancer with cutaneous metastasis.
    Xu Y; Ding L; Li C; Hua B; Wang S; Zhang J; Liu C; Guo R; Zhang Y
    Diagn Pathol; 2024 Jul; 19(1):93. PubMed ID: 38970069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
    Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
    Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
    Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
    Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
    Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
    Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
    Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.